Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + melphalan + prednisone in elderly patients with multiple myeloma
ChiCTR2400084725Phase 4Not yet recruiting
- Sponsor
- Qingdao Municipal Hospital
- Start
- May 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ixazomib, melphalan and prednisone in multiple myeloma (MM), sponsored by Qingdao Municipal Hospital. Primary endpoint: Overall response rate. Planned start May 2024; status: not yet recruiting.
02
Drugs
ixazomibmelphalanprednisone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ChiCTR2400084725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084725.